Get the Stockscreener App
331.81
0.54%
1.79
After Hours:
331.18
-0.63
-0.19%
Praxis Precision Medicines Inc stock is traded at $331.81, with a volume of 674.34K.
It is up +0.54% in the last 24 hours and up +4.96% over the past month.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.
See More
Previous Close:
$330.02
Open:
$333.53
24h Volume:
674.34K
Relative Volume:
1.62
Market Cap:
$9.25B
Revenue:
$7.46M
Net Income/Loss:
$-303.27M
P/E Ratio:
-24.64
EPS:
-13.4668
Net Cash Flow:
$-249.12M
1W Performance:
-1.72%
1M Performance:
+4.96%
6M Performance:
+80.76%
1Y Performance:
+765.22%
1-Day Range:
$327.89
$341.26
1-Week Range:
$317.92
$353.00
52-Week Range:
$35.21
$356.00
Praxis Precision Medicines Inc Stock (PRAX) Company Profile
Name
Praxis Precision Medicines Inc
Sector
Industry
Phone
617-300-8460
Address
99 HIGH STREET, 30TH FLOOR, BOSTON
Compare PRAX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PRAX
Praxis Precision Medicines Inc
|
331.81 | 9.20B | 7.46M | -303.27M | -249.12M | -13.47 |
VRTX
Vertex Pharmaceuticals Inc
|
435.17 | 109.09B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
712.77 | 74.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
813.28 | 48.64B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
284.84 | 39.39B | 4.29B | 577.22M | 641.34M | 4.2086 |
ONC
Beone Medicines Ltd Adr
|
310.75 | 32.38B | 5.36B | 287.73M | 924.18M | 2.5229 |
Praxis Precision Medicines Inc Stock (PRAX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-26 | Initiated | Raymond James | Strong Buy |
| Feb-24-26 | Initiated | Wolfe Research | Outperform |
| Feb-02-26 | Initiated | Wells Fargo | Equal Weight |
| Dec-15-25 | Reiterated | Oppenheimer | Outperform |
| Nov-19-25 | Initiated | BTIG Research | Buy |
| Jun-02-25 | Resumed | Oppenheimer | Outperform |
| May-07-25 | Initiated | Chardan Capital Markets | Buy |
| Mar-03-25 | Reiterated | H.C. Wainwright | Buy |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Aug-05-24 | Initiated | Oppenheimer | Outperform |
| Jun-24-24 | Initiated | Needham | Buy |
| Jun-18-24 | Initiated | Guggenheim | Buy |
| May-01-24 | Initiated | Robert W. Baird | Outperform |
| Sep-19-23 | Initiated | Truist | Buy |
| Jun-06-22 | Downgrade | Wedbush | Outperform → Neutral |
| Dec-16-21 | Initiated | H.C. Wainwright | Buy |
| Aug-26-21 | Initiated | BofA Securities | Buy |
| Apr-26-21 | Initiated | William Blair | Outperform |
| Nov-11-20 | Initiated | Wedbush | Outperform |
| Nov-10-20 | Initiated | Cowen | Outperform |
| Nov-10-20 | Initiated | Evercore ISI | Outperform |
| Nov-10-20 | Initiated | Piper Sandler | Overweight |
View All
Praxis Precision Medicines Inc Stock (PRAX) Latest News
Praxis Precision Medicines Maps High-Stakes Launch Path - TipRanks
Wedbush Maintained an Underperform Rating on Praxis Precision Medicines, Inc. (PRAX) - Yahoo Finance Singapore
10 Best Biotech Stocks to Invest In According to Billionaire Steve Cohen - Insider Monkey
LifeSci Capital Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $795 - Moomoo
A Quick Look at Today's Ratings for Praxis Precision Medicines(PRAX.US), With a Forecast Between $166 to $1,245 - Moomoo
Number of shareholders of Praxis Precision Medicines, Inc. – NASDAQ:PRAX - TradingView
Praxis Precision Medicines Q1 Earnings Call Highlights - TradingView
Praxis Precision Medicines, Inc.Common Stock (Nasdaq:PRAX) Stock Quote - FinancialContent
PRAX Maintained by Wedbush -- Price Target Raised to $166.00 - GuruFocus
Deutsche Bank Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Cuts Target Price to $420 - Moomoo
A Quick Look at Today's Ratings for Praxis Precision Medicines(PRAX.US), With a Forecast Between $441 to $1,245 - Moomoo
Praxis Precision Medicines, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Deutsche Bank Adjusts Praxis Precision Medicines Price Target to $420 From $444, Maintains Buy Rating - marketscreener.com
PRAX Reiterated by BTIG -- Price Target Maintained at $843 - GuruFocus
Praxis Precision Medicines, Inc (PRAX): Investor Outlook on a Biotechnology Challenger with 90% Upside Potential - DirectorsTalk Interviews
TD Cowen Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $554 - Moomoo
PRAX Stock Price, Quote & Chart | PRAXIS PRECISION MEDICINES I (NASDAQ:PRAX) - ChartMill
Praxis Precision Medicines Q1 2026: Loss Narrows 12.1% to -$3.20/Share - AlphaStreet
JonesTrading Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $441 - Moomoo
Needham Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Raises Target Price to $537 - Moomoo
Jefferies raises Praxis Precision Medicines stock price target on pipeline catalysts - Investing.com UK
Wolfe Research initiates coverage of Praxis Precision Medicines (PRAX) with outperform recommendation - MSN
Earnings call transcript: Praxis Precision beats Q1 2026 EPS forecasts By Investing.com - Investing.com Australia
Earnings call transcript: Praxis Precision beats Q1 2026 EPS forecasts - Investing.com
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results - Investing News Network
PRAX: Two NDAs accepted, strong clinical momentum, and $1.4B cash support launches in 2026 - TradingView
Praxis Precision Medicines Q1 2026 Earnings Call Transcript - MarketBeat
Praxis Precision Medicines 1Q 2026: Net loss $(92.6M), EPS $(3.20) — 10-Q Summary - TradingView
Praxis (PRAX) secures $1.4B cash as epilepsy and tremor NDAs advance - Stock Titan
Q1 2026 Praxis Precision Medicines Inc Earnings Call Transcript - GuruFocus
A seizure drug cut monthly seizures 77% as Praxis nears 2 FDA calls - Stock Titan
Press Release: Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results - Moomoo
Praxis earnings up next as biotech nears commercial transformation - Investing.com UK
LifeSci Capital Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Raises Target Price to $795 - Moomoo
FMR LLC holds 7.7% of Praxis Precision Medicines (PRAX) — 2.16M shares - Stock Titan
Price-Driven Insight from (PRAX) for Rule-Based Strategy - Stock Traders Daily
Praxis gives 21 new employees stock awards tied to hiring - Stock Titan
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Praxis Precision Medicines Inc expected to post a loss of $3.57 a shareEarnings Preview - TradingView
Praxis Precision Medicines (PRAX.US) will release its earnings report before the market opens on May 7. - Moomoo
Praxis Precision Medicines to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026, and Participate in Upcoming Investor Conference - The Manila Times
Praxis maps out two investor events in May, starting with Q1 results - Stock Titan
Praxis (PRAX) Aligns Pay With Ulixacaltamide Progress Is Incentive Design Now a Key Edge? - Yahoo Finance
A Look At Praxis Precision Medicines (PRAX) Valuation After Strong Long Term Shareholder Returns - Yahoo Finance
Praxis (NASDAQ: PRAX) details 2026 virtual meeting, director slate and Say-on-Pay - Stock Titan
Vanguard (NASDAQ: PRAX) reports 1.42M shares, 5.09% stake in Praxis - Stock Titan
LifeSci Capital Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $567 - Moomoo
Analysts Project Growth for Praxis Precision Medicines Biotech Stock - HarianBasis.co
Optimism Surrounds Praxis Precision Medicines (PRAX) Amid Potential FDA Approval for Ulixacaltamide - Insider Monkey
Moody Aldrich Partners LLC Buys New Position in Praxis Precision Medicines, Inc. $PRAX - MarketBeat
Pictet Asset Management Holding SA Makes New $71.09 Million Investment in Praxis Precision Medicines, Inc. $PRAX - MarketBeat
Praxis Precision Medicines Inc Stock (PRAX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.70%
2.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):